News
LXRX
2.405
+3.22%
0.075
U.S. RESEARCH ROUNDUP-Alexander & Baldwin, Instructure Holdings, RPM International
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Alexander & Baldwin, Instructure Holdings, RPM International and UnitedHealth Group among companies. American Airlines, Apple and Abbvie among companies with revised targets. The analysts also raised their ratings on several other companies.
Reuters · 18h ago
LEXICON PHARMACEUTICALS INC <LXRX.O>: JEFFERIES RAISES TARGET PRICE TO $2.25 FROM $2
Reuters · 21h ago
Weekly Report: what happened at LXRX last week (0715-0719)?
Weekly Report · 4d ago
Optimistic Outlook for Lexicon Pharmaceuticals: FDA Advances and Strategic Catalysts Poised to Enhance Market Position
TipRanks · 07/18 06:49
Lexicon Pharma Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 07/16 17:40
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target
Benzinga · 07/16 17:30
Lexicon gains as diabetes therapy undergoes FDA review
Lexicon Pharmaceuticals, Inc. (LXRX) traded higher on Tuesday. The company said the FDA accepted its resubmitted marketing application for diabetes therapy, Zynquista, for review. In 2019, the FDA rejected the company's application for the drug.
Seeking Alpha · 07/16 14:02
Buy Rating Affirmed on Lexicon Pharmaceuticals Amid Promising Sotagliflozin Trials and Upcoming PDUFA Date
TipRanks · 07/16 13:45
Piper Sandler Reaffirms Their Buy Rating on Lexicon Pharmaceuticals (LXRX)
TipRanks · 07/16 12:16
LEXICON- FDA INDICATED IT CONSIDERS RESUBMISSION TO BE COMPLETE RESPONSE TO FDA'S 2019 ACTION LETTER REGARDING SOTAGLIFLOZIN NDA FOR TYPE 1 DIABETES
Reuters · 07/16 12:01
Weekly Report: what happened at LXRX last week (0708-0712)?
Weekly Report · 07/15 09:21
Lexicon Pharmaceuticals Insider Buyers See Boost After Market Cap Rose US$72m
Lexicon Pharmaceuticals, Inc. Insiders bought US$72m worth of shares in the last year. The company's share price rose 12% last week. The biggest insider purchase was US$1.1m by Raymond Debbane for US$2.45m. In the past year Lexicon pharmaceuticals insiders have bought about US$6.9m of shares. It's important to pay attention to whether insiders are buying or selling shares in a company. Lexicon Pharmas has a 1.2% stake in the company.
Simply Wall St · 07/12 17:32
Executive reshuffles: ChargePoint, Tupperware and ADM in focus
Executive reshuffles: ChargePoint, Tupperware and ADM in focus. Several Wall Street executives stepped up for new roles as part of leadership reshuffling. Some companies such as ChargePoint and ADm added new positions to steer growth prospects to new positions.
Seeking Alpha · 07/12 16:15
Strategic Leadership and Pipeline Promise: A Buy Rating for Lexicon Pharmaceuticals
TipRanks · 07/12 07:16
Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?
NASDAQ · 07/09 10:54
Lexicon appoints Mike Exton as CEO, Jeff Wade as COO
Healthcare Lexicon appoints Mike Exton as CEO, Jeff Wade as COO. Exton succeeds Lonnel Coats who retired effective July 7, 2024. Jeff Wade has been named president and COO of Lexicon. Lexicon Pharmaceuticals, Inc. (LXRX) stock.
Seeking Alpha · 07/08 17:11
Lexicon Pharmaceuticals Welcomes New CEO and COO
TipRanks · 07/08 13:47
Lexicon Pharmaceuticals Names Novartis Mike Exton as CEO
Dow Jones · 07/08 13:30
Lexicon Appoints Mike Exton As New Chief Executive Officer And Director Succeeding Lonnel Coats Who, As Previously Announced, Retired Effective July 7, 2024
Lexicon Pharmaceuticals appoints Mike Exton, Ph.D. As chief executive officer and director. Exton most recently served as the global cardiometabolic therapeutic head at Novartis. He succeeds Lonnel Coats, who retired effective July 7, 2024.
Benzinga · 07/08 13:21
Press Release: Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
Dow Jones · 07/08 13:15
More
Webull provides a variety of real-time LXRX stock news. You can receive the latest news about Lexicon Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.